AstraZeneca Settles Seroquel Allegations For $68.5 Million
The company that makes the schizophrenia drug Seroquel has agreed to a settlement with 38 states for $68.5 million. The deal resolves allegations of deceptive marketing practices. It's the second time in the last year that AstraZeneca has reached a government settlement for how it's marketed Seroquel. But this deal is small compared to last year when it agreed to pay $520 million to settle federal investigations. Attorneys general made similar claims as the federal government: That it paid doctors to market the drug for unapproved uses for things such as dementia, sleep disorders and post-traumatic stress disorder. North Carolina's portion of the settlement is $2.4 million. "It's dangerous to push medications as treatments for conditions they haven't been proven to treat. Patients and doctors deserve accurate information about drugs, not to be misled by tricky marketing," North Carolina Attorney General Roy Cooper said in a prepared statement. AstraZeneca denies the allegations but says it's in the company's best interest to resolve them. The settlement prohibits AstraZeneca from rewarding doctors for their prescribing habits. It must also post on its web site payments made to doctors.